Takagi T and Takahiko I et al. demonstrated that CDDO-Me treatment could improve neurological symptoms, reduce intracranial hemorrhage and ameliorate BBB disruption in cerebral ischemia–reperfusion injury due to the activation of Nrf2 and its target genes in neurons and astrocytes [56, 57]. This evidence concerns the gene NFE2L2 and intracranial hemorrhage.